Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients

Almeida, Valéria de; Alexandrino, Guilherme L.; Aquino, Adriano; Gomes, Alexandre F.; Murgu, Michael; Dobrowolny, Henrik; Guest, Paul C.; Steiner, Johann; Martins‐de‐Souza, Daniel

doi:10.1016/j.pnpbp.2020.109945

Cited by 28 publications

(20 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This phenomenon to a certain degree may explain the lack of difference in serum FAs between SZ and HC groups. Antipsychotic medication increases the expression and activity of enzymes involved in PUFA metabolism, and changes in the blood plasma lipidome are suggested as a treatment response in psychiatric disorders [5]. On the other hand, in our study, the nutritional assessment concerned short-term omega-3 intake.…”

Section: Discussionmentioning

confidence: 82%

“…The mechanism of undernutrition of PUFAs in the SZ population is still under examination. Studies indicated that several factors engage in improper FA blood concentrations, including poor nutrition, antipsychotic drug interactions with cell membranes, and disturbances of lipid metabolism, as well as fatty acid-dependent signaling pathways [2,3,5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of GPR120 Receptor in Essential Fatty Acids Metabolism in Schizophrenia

et al. 2020

View full text Add to dashboard Cite

A growing body of evidence confirms abnormal fatty acid (FAs) metabolism in the pathophysiology of schizophrenia. Omega-3 polyunsaturated fatty acids (PUFAs) are endogenous ligands of the G protein-coupled receptors, which have anti-inflammatory properties and are a therapeutic target in many diseases. No clinical studies are concerned with the role of the GPR120 signaling pathway in schizophrenia. The aim of the study was to determine the differences in PUFA nutritional status and metabolism between patients with schizophrenia (SZ group) and healthy individuals (HC group). The study included 80 participants (40 in the SZ group, 40 in the HC group). There were no differences in serum GPR120 and PUFA concentrations and PUFA intake between the examined groups. In the HC group, there was a relationship between FAs in serum and GPR120 concentration (p < 0.05): α-linolenic acid (ALA) (R = −0.46), docosahexaenoic acid (DHA) (R = −0.54), omega-3 PUFAs (R = −0.41), arachidonic acid (AA) (R = −0.44). In the SZ group, FA serum concentration was not related to GPR120 (p > 0.05). In the HC group, ALA and DHA serum concentrations were independently associated with GPR120 (p < 0.05) in the model adjusted for eicosapentaenoic acid (EPA) and accounted for 38.59% of GPR120 variability (p < 0.05). Our results indicate different metabolisms of FAs in schizophrenia. It is possible that the diminished anti-inflammatory response could be a component connecting GPR120 insensitivity with schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Introductionmentioning

confidence: 99%

The Role of GPR120 Receptor in Essential Fatty Acids Metabolism in Schizophrenia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In agreement with the study by Cai et al elevated levels of LPCs were also observed in RBCs and plasma samples from schizophrenia patients versus control individuals in another study 42 . Most recently, De Almeida and colleagues assessed alterations in the blood plasma lipidome in schizophrenia patients before and after treatment with atypical antipsychotics, and noted that some PCs were increased in response to antipsychotics 43 . It is worth noting that the differences in lipids between schizophrenia and control subjects in previous studies are inconsistent.…”

Section: Aberrant Lipidome In Schizophrenia As Revealed By Lipidomicsmentioning

confidence: 99%

Lipidomics of the brain, retina, and biofluids: from the biological landscape to potential clinical application in schizophrenia

et al. 2020

View full text Add to dashboard Cite

Schizophrenia is a serious neuropsychiatric disorder, yet a clear pathophysiology has not been identified. To date, neither the objective biomarkers for diagnosis nor specific medications for the treatment of schizophrenia are clinically satisfactory. It is well accepted that lipids are essential to maintain the normal structure and function of neurons in the brain and that abnormalities in neuronal lipids are associated with abnormal neurodevelopment in schizophrenia. However, lipids and lipid-like molecules have been largely unexplored in contrast to proteins and their genes in schizophrenia. Compared with the gene- and protein-centric approaches, lipidomics is a recently emerged and rapidly evolving research field with particular importance for the study of neuropsychiatric disorders such as schizophrenia, in which even subtle aberrant alterations in the lipid composition and concentration of the neurons may disrupt brain functioning. In this review, we aimed to highlight the lipidomics of the brain, retina, and biofluids in both human and animal studies, discuss aberrant lipid alterations in correlation with schizophrenia, and propose future directions from the biological landscape towards potential clinical applications in schizophrenia. Recent studies are in support of the concept that aberrations in some lipid species [e.g. phospholipids, polyunsaturated fatty acids (PUFAs)] lead to structural alterations and, in turn, impairments in the biological function of membrane-bound proteins, the disruption of cell signaling molecule accessibility, and the dysfunction of neurotransmitter systems. In addition, abnormal lipidome alterations in biofluids are linked to schizophrenia, and thus they hold promise in the discovery of biomarkers for the diagnosis of schizophrenia.

show abstract

“…On the other hand, the study of changes over time in lipid levels of the same individual has the advantage of reducing this variability. Previously, several studies have aimed to investigate the association between changes in blood lipidome composition and symptom improvement for schizophrenia [ 31 , 32 , 33 ], but the available evidence is limited. In this study, we measured the blood lipid abundances in 92 individuals diagnosed with schizophrenia and undergoing inpatient treatment.…”

Section: Introductionmentioning

confidence: 99%

Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia

et al. 2021

View full text Add to dashboard Cite

Schizophrenia is a serious mental disorder requiring lifelong treatment. While medications are available that are effective in treating some patients, individual treatment responses can vary, with some patients exhibiting resistance to one or multiple drugs. Currently, little is known about the causes of the difference in treatment response observed among individuals with schizophrenia, and satisfactory markers of poor response are not available for clinical practice. Here, we studied the changes in the levels of 322 blood plasma lipids between two time points assessed in 92 individuals diagnosed with schizophrenia during their inpatient treatment and their association with the extent of symptom improvement. We found 20 triglyceride species increased in individuals with the least improvement in Positive and Negative Syndrome Scale (PANSS) scores, but not in those with the largest reduction in PANSS scores. These triglyceride species were distinct from the rest of the triglyceride species present in blood plasma. They contained a relatively low number of carbons in their fatty acid residues and were relatively low in abundance compared to the principal triglyceride species of blood plasma.

show abstract

Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients

Cited by 28 publications

References 58 publications

The Role of GPR120 Receptor in Essential Fatty Acids Metabolism in Schizophrenia

The Role of GPR120 Receptor in Essential Fatty Acids Metabolism in Schizophrenia

Lipidomics of the brain, retina, and biofluids: from the biological landscape to potential clinical application in schizophrenia

Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia

Contact Info

Product

Resources

About